Skip to Content

Join the 'Keveyis' group to help and get support from people like you.

Keveyis News

FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Posted 10 Aug 2015 by

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 10, 2015-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis [1]. Keveyis is ...

Ask a Question

Further Information

Related Condition Support Groups

Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis, Primary Periodic Paralysis

Keveyis Patient Information at